Dec 31, 2025 • MarketBeat
NEUTRAL
Allspring Global Investments Holdings LLC Sells 113,185 Shares of Charles River Laboratories International, Inc. $CRL
Allspring Global Investments Holdings LLC reduced its stake in Charles River Laboratories International (NYSE:CRL) by 4.9%, selling 113,185 shares. The firm now holds 2,177,941 shares, valued at approximately $371.3 million, making CRL its 21st biggest holding. Other institutional investors have also adjusted their positions, with several increasing their holdings in the medical research company.
Dec 30, 2025 • openPR.com
SOMEWHAT-BULLISH
Cell Therapy Manufacturing Market Forecast Through 2032
The global cell therapy manufacturing market is projected to reach USD 15.14 billion by 2032, growing at a CAGR of 15.1% from USD 5.65 billion in 2025. Coherent Market Insights' report provides detailed analysis including segmentation by therapy type, technology, manufacturing purpose, and application, alongside profiles of key companies. The study aims to help decision-makers navigate the evolving market and capitalize on upcoming opportunities in this rapidly innovating sector.
Dec 30, 2025 • MarketBeat
BULLISH
Charles River Laboratories International, Inc. $CRL Shares Purchased by Boston Trust Walden Corp
Boston Trust Walden Corp increased its stake in Charles River Laboratories International (NYSE:CRL) by 36.4% in the third quarter, owning 307,242 shares valued at $48.07 million. Several other institutional investors also adjusted their positions in CRL, with hedge funds and institutional investors owning 98.91% of the stock. Analyst ratings for Charles River Laboratories show a "Moderate Buy" consensus with a target price of $195.93.
Dec 30, 2025 • AD HOC NEWS
NEUTRAL
Charles River Laboratories Stock Tests Investor Patience as Biopharma Recalibrates
Charles River Laboratories (CRL) stock is currently in a complex market phase due to biopharma headwinds, regulatory concerns, and cautiously optimistic future growth prospects. While the company is strategically important in preclinical research and biologics testing, its stock performance has lagged the broader market, prompting investor patience. Wall Street analysts generally rate CRL as "Buy" or "Overweight," seeing the stock as undervalued for its long-term potential, despite near-term uncertainties in biopharma spending and regulatory risks.
Dec 29, 2025 • MarketBeat
SOMEWHAT-BULLISH
Charles River Laboratories International, Inc. $CRL Stake Cut by Norris Perne & French LLP MI
Norris Perne & French LLP MI significantly reduced its stake in Charles River Laboratories International (NYSE:CRL) by 92% in Q3, selling over 110,000 shares. Despite this, other institutional investors have recently increased their positions, and Charles River Laboratories reported strong Q3 earnings, beating analyst estimates with $2.43 EPS and $1 billion in revenue. The company maintains a "Moderate Buy" analyst consensus with a target price around $195.93.
Dec 29, 2025 • MarketBeat
SOMEWHAT-BULLISH
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Moderate Buy" from Analysts
Charles River Laboratories International, Inc. (NYSE:CRL) has received an average rating of "Moderate Buy" from eighteen analyst firms, with a consensus 12-month average target price of $195.93. Several analysts recently adjusted their price targets, indicating continued interest in the stock. Despite trading near its 52-week high and institutional ownership of nearly 99%, the company reported a negative P/E ratio and net margin, reflecting recent margin pressures.